Cel-Sci: Fabulous Story Stock Works To Pass Muster With FDA [Seeking Alpha]
Cel-Sci Corporation (CVM)
NASDAQ:AMEX Investor Relations:
cel-sci.com/investor_relations.html
Company Research
Source: Seeking Alpha
I am a long-term follower and chronicler of CEL-SCI ( NYSE: CVM ). My initial CEL-SCI article was 08/2019's CEL-SCI: A Risky Bet. My most recent was 07/2023's "Cel-Sci: Would-Be Cancer Giant Taking Baby Steps". In this article I evaluate its investment prospects based up on its latest investor communications. These include: 10/25/2023 - Shareholder Letter From The CEO (the " Letter 01/25/2024 - CEL-SCI Multikine Pre-Surgical Cancer Therapy Presentation (the " Presentation 12/22/2023 - Fiscal 2023 Financial Results and Clinical & Corporate Developments (the " Results 12/21/2023 - 10-K for the fiscal year ended September 30, 2023 (the " 10-K The CEL-SCI's Multikine story is intuitively appealing CEL-SCI is all about its cancer pretreatment therapy Multikine (Leukocyte Interleukin, Injection). It is an immunotherapy consisting of a cocktail of cytokines and select small biological molecules. Critically it is administered at the outset of one's cancer treatment before treat
Show less
Read more
Impact Snapshot
Event Time:
CVM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CVM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CVM alerts
High impacting Cel-Sci Corporation news events
Weekly update
A roundup of the hottest topics
CVM
News
- CEL-SCI Appoints Mario Gobbo to Its Board of Directors [Yahoo! Finance]Yahoo! Finance
- CEL-SCI Appoints Mario Gobbo to Its Board of DirectorsBusiness Wire
- CEL-SCI's LEAPS Vaccine Offers Promising New Paradigm to Treat Rheumatoid Arthritis: Published in Frontiers in Immunology [Yahoo! Finance]Yahoo! Finance
- CEL-SCI’s LEAPS Vaccine Offers Promising New Paradigm to Treat Rheumatoid Arthritis: Published in Frontiers in ImmunologyBusiness Wire
- CEL-SCI Co. (NYSE: CVM) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.MarketBeat
CVM
Sec Filings
- 4/23/24 - Form 3
- 4/23/24 - Form 4
- 4/23/24 - Form 4
- CVM's page on the SEC website